fostamatinib + Microgynon® 30 (Oral contraceptive) + Placebo
Phase 1CompletedDevelopment Stage
Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug Interaction
Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug Interaction, Laymen Terminology Level of Oral Contraceptive in Blood, Oral Contraceptive, Rheumatoid Arthritis, Drug -Drug Interaction
Mar 1, 2011 → Nov 1, 2011
About fostamatinib + Microgynon® 30 (Oral contraceptive) + Placebo
fostamatinib + Microgynon® 30 (Oral contraceptive) + Placebo is a phase 1 stage product being developed by AstraZeneca for Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug Interaction. The current trial status is completed. This product is registered under clinical trial identifier NCT01276262. Target conditions include Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug Interaction, Laymen Terminology Level of Oral Contraceptive in Blood, Oral Contraceptive, Rheumatoid Arthritis, Drug -Drug Interaction.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01276262 | Phase 1 | Completed |
Competing Products
2 competing products in Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug Interaction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Veliparib | AbbVie | Pre-clinical | 23 |
| Placebo + AZD5069 50mg + AZD5069 80mg | AstraZeneca | Phase 2 | 52 |